Phillip Morris Invests $20m in Syqe Cannabis Inhaler

Phillip Morris and Syqe, an Israeli medical device company with an inhaler type delivery system have announced a $20m investment.  The cigarette manufacturer will benefit  from a Medtech footprint to understand the potential to significantly reduce damage from smoking traditional nicotine products.

A study at Rambam Hospital where the cannabis inhaler was examined, reported it both safe and effective. In Israel there is an estimated 24, 000  medical cannabis patients.

The Syqe cannabis inhaler is changing the way medical cannabis users consume the plant, and allows the use of material with the minimum of risk to the health of the patient. The company also has an inhaler for allowing hospitals to provide patients with accurate doses automatically.

The investment by Philip Morris is part of a larger $30 million investment package raised by Syqe Medical. Syqe also receives funds from existing investors, including the investment fund through leading Israeli crowdfunding platform OurCrowd, founders of Retalix; Barry...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.